Research Papers:

Abnormal amphiregulin expression correlates with gastric cancer prognosis

Bing Wang, Hongmei Yong, Huijun Zhu, Daguang Ni, Sijie Tang, Shu Zhang, Wei Wang, Yan Zhou, Wei Zhao, Guipeng Ding, Jin Zhu, Xiaohua Li and Zhenqing Feng _

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:76684-76692. https://doi.org/10.18632/oncotarget.12436

Metrics: PDF 1689 views  |   HTML 2846 views  |   ?  


Bing Wang1,2, Hongmei Yong3, Huijun Zhu4, Daguang Ni1, Sijie Tang1, Shu Zhang4, Wei Wang4, Yan Zhou2, Wei Zhao5, Guipeng Ding5, Jin Zhu6, Xiaohua Li1,7,8, Zhenqing Feng2,5,9,10

1Center for Pathology and Laboratory Medicine, Zhangjiagang Ao Yang Hospital, Zhangjiagang, Jiangsu, China

2Department of Oncology, Zhangjiagang Ao Yang Hospital, Zhangjiagang, Jiangsu, China

3Department of Oncology, Huai’an Hospital Affiliated of Xuzhou Medical College and Huai’an Second People’s Hospital, Huai’an, Jiangsu, China

4Department of Pathology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China

5Department of Pathology, Nanjing Medical University, Nanjing, China

6Huadong Medical Institute of Biotechniques, Nanjing, China

7School of Medicine, Jiangsu University, Jiangsu, China

8The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China

9Key Laboratory of Antibody Technique of Ministry of Health, Nanjing Medical University, Nanjing, China

10Jiangsu Collaborative Innovation Center For Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China

Correspondence to:

Xiaohua Li, email: [email protected]

Zhenqing Feng, email: [email protected]

Keywords: gastric cancer, amphiregulin, prognosis

Received: April 05, 2016     Accepted: September 27, 2016     Published: October 04, 2016


Gastric cancer (GC) is a global health issue with a high mortality rate. Early diagnosis and tracking of GC is a challenge due to a lack of reliable tools. Amphiregulin (AREG) is a member of the epidermal growth factor (EGF) family that activates growth signaling upon binding of EGF receptors. Elevated AREG expression is associated with various pathological conditions, including cancer. Here, we investigated whether increased AREG expression is a disease indicator and/or prognostic biomarker for GC. We used tissue microarray and quantitative real-time polymerase chain reaction to assess AREG expression in clinical tissue specimens at various stages of GC and a conducted bioinformatics analysis to evaluate the value of AREG over-expression as a GC biomarker. We found that both mRNA and protein expression of AREG were increased in the tissues of GC patients when compared to tissues from non-cancer patients or normal tissues. High expression of AREG was also associated with GC clinicopathological characteristics and poor survival. Thus, over-expression of AREG could serve as a novel GC biomarker, and active surveillance of its expression could be a novel approach to GC diagnosis and monitoring.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 12436